Just saw Intellia (NTLA) popped 3.56% to $14.27 after FDA finally lifted the hold on their MAGNITUDE Phase 3 trial. They had to pause things back in October when one patient hit some liver issues, but looks like they cleared it. The hold on is off now and they're moving forward with enrollment.



What's interesting is they already resolved the hold on the MAGNITUDE-2 trial back in January too. CEO basically said now they can focus on finishing both trials. This is a pretty big deal for their ATTR cardiomyopathy treatment (nexiguran ziclumeran). If this works out, could be massive for that patient population. Market seems to be buying it.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin